Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sutro Biopharma, Inc. (STRO : NSDQ)

• Company Description    Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. Number of Employees: 224

• Price / Volume Information    Yesterday's Closing Price: $4.74 Daily Weekly Monthly 20 Day Moving Average: 587,231 shares Shares Outstanding: 46.93 (millions) Market Capitalization: $222.47 (millions) Beta: 1.11 52 Week High: $23.70 52 Week Low: $4.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -30.40% -23.73% 12 Week -44.04% -39.28% Year To Date -68.14% -62.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 111 Oyster Point Blvd - South San Francisco,CA 94080 USA ph: 650-881-6500 fax: - ajchang@sutrobio.com http://www.sutrobio.com

• General Corporate Information    Officers William J. Newell - President; Chief Executive Officer Edward C. Albini - Chief Financial Officer and Corporate Secretary Michael Dybbs - Director John G. Freund - Director Joseph M. Lobacki - Director Peer Information Sutro Biopharma, Inc. (CORR.) Sutro Biopharma, Inc. (RSPI) Sutro Biopharma, Inc. (CGXP) Sutro Biopharma, Inc. (BGEN) Sutro Biopharma, Inc. (GTBP) Sutro Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 869367102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 46.93 Most Recent Split Date: (:1) Beta: 1.11 Market Capitalization: $222.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.70 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.01 Price/Cash Flow: - Price / Sales: 4.19 EPS Growth vs. Year Ago Period: -95.35% vs. Previous Quarter: -1.20% Sales Growth vs. Year Ago Period: -59.77% vs. Previous Quarter: -44.65% ROE 03/31/22 - -42.97 12/31/21 - -32.96 09/30/21 - -37.80 ROA 03/31/22 - -33.22 12/31/21 - -26.51 09/30/21 - -31.34 Current Ratio 03/31/22 - 5.90 12/31/21 - 5.24 09/30/21 - 7.07 Quick Ratio 03/31/22 - 5.90 12/31/21 - 5.24 09/30/21 - 7.07 Operating Margin 03/31/22 - -215.16 12/31/21 - -153.28 09/30/21 - -195.40 Net Margin 03/31/22 - -215.16 12/31/21 - -170.55 09/30/21 - -213.36 Pre-Tax Margin 03/31/22 - -215.16 12/31/21 - -170.55 09/30/21 - -213.36 Book Value 03/31/22 - 4.70 12/31/21 - 5.46 09/30/21 - 6.15 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.06 12/31/21 - 0.06 09/30/21 - 0.07 Debt-to-Capital 03/31/22 - 5.47 12/31/21 - 5.87 09/30/21 - 6.19

Powered by Zacks Investment Research ©